Wake Forest University

PALO ALTO, Calif., Sept. 5, 2024 /PRNewswire/ -- SageMedic Corp (also known as 'SAGE'), a Silicon Valley-based rising star in cancer diagnostics, is excited to announce the formation of its Scientific and Medical Advisory Board (SAB). Comprised of distinguished authorities in cancer research and medical and surgical oncology, the board reflects SageMedic's commitment to significantly enhance the precision of cancer diagnostics by enabling oncologists to more effectively tailor therapies to individual patient needs. William Cance, MD, former Chief Medical and Scientific Officer at the American Cancer Society, leads the Scientific and Medical Advisory Board. According to Dr. Cance, "Cancer poses profound challenges, with many advancements offering only marginal benefits to patients. However, SAGE's innovative approach—testing cancer therapy options on the patient's own live tumor tissue with in vitro results in just 7-10 days—holds the promise of a transformational advancement in precision medicine with dramatically improved patient outcomes." Jorg Dietrich, MD, PhD, MBA, Director of the Cancer & Neurotoxicity Clinic and Brain Repair Research Program at Massachusetts General Hospital (MGH) and Harvard Medical School, is a leading voice in glioblastoma, brain tumor biology, and cancer therapy. Amer Karam, MD, Clinical Professor and Director of Robotic Surgery in Gynecologic Oncology at Stanford University, is an esteemed gynecologic oncologist with longstanding interest in chemosensitivity testing and expertise in minimally invasive cancer surgery, advising and collaborating with SAGE in ovarian cancer. Scott Kopetz, MD, PhD, Deputy Chair for Translational Research in the Department of Gastrointestinal (GI) Medical Oncology at MD Anderson Cancer Center, is known for his translational research in gastrointestinal cancers, including in-vitro organoid models. Priya Kumthekar, MD, Associate Professor of Neurology at the Northwestern University Feinberg School of Medicine, is focused on innovative therapeutic approaches for central nervous system (CNS) malignancies, including primary and metastatic brain tumors. Konstantinos Votanopoulos, MD, PhD, Professor of Surgery at Atrium Health Wake Forest Baptist Comprehensive Cancer Center and Director of the Organoid Research Center at Wake Forest University, collaborates with SAGE in predicting response to immuno-oncology therapeutics. Chris Apfel, MD, MBA, Chair & CEO of SageMedic, expressed his enthusiasm: "We are honored to have such a prestigious group of key opinion leaders join our SAB. Their unparalleled expertise will continue to push the boundaries of what is possible in precision medicine to truly personalize therapies for cancer patients." About SageMedic Corp: SageMedic Corp is at the forefront of developing diagnostic solutions that significantly improve treatment outcomes in oncology. Through the innovative SAGE Oncotest™, an AI-augmented, in-vitro, live 3D microtumor approach, the company provides actionable insights that allow oncologists to devise personalized treatment strategies, enhancing the quality of life for cancer patients across the globe. For inquiries or further information about SageMedic, please direct communications to: Mara Quigley, Co-President, Steve Allen Media (661) 255-8283 [email protected] SOURCE SageMedic Corp

一幢巴洛克风格的建筑立于老汉口街头博物馆黎黄陂路38号：旧俄租界，砖混结构，三层立面，活泼自由，独体民居，保存完好。建筑年代推测为20世纪30年代，殖民外廊式，坡瓦顶上拱券老虎窗，清水红砖外墙保存原有风貌。 此乃爱国人士高维舟于“九一八事变”爆发后置下的一处房产——进可作其事业起点，退可为其生活保障。而高维舟的长女，正是20世纪上半叶留美的医学博士，中国著名妇科专家，“北有林巧稚、南有高欣荣”一说中的高欣荣，曾任武汉市第二医院妇科主任。高新荣的两位弟弟高有焕和高有炳分别为内科专家和外科专家。姐弟三人在武汉医学界赫赫有名。 1948年，高氏三姐弟留学回国参照“美式前医院后研究所”的模式经验，以汉口房产为基地创办高氏医院。高氏医院彼时名扬武汉三镇，设内、外、妇三科，开设门诊以及住院服务，除一般诊疗外可以施行小型手术，收费低廉面向平民。1952年高氏医院停办全部人员加入市立医院。    研发团队赓续历史荣光、 传承武汉医科所精神 之后在高氏医院一路之隔对门的黎黄陂路47号（原汉口新华广播电台旧址）正式成立武汉市医学科学研究所，高有炳任首任所长，在上世纪70-80年代专注于中医药科研和学术传播。上世纪90年代，留学归国博士游上游所长时期开始转向抗体科学研究，并于1997年获批建立第一个抗体新型研发机构——武汉市抗体研究中心。 2023年，武汉市医科所有限责任公司（简称武汉医科所）正式成立，首席科学家团队来自于体制内一类科研事业单位武汉市医学科学研究所。科研技术人员响应国家号召下海特区离岗创新创业——定位于新型医科研发机构创办企业，距今半个世纪历史赓续变革与时俱进。 图片源自武汉医科所 目前武汉市医科所有限责任公司隶属于中国低温医学科技集团（香港），下设“生物谷”投资基金（注册商标唯一获得国家知识产权局审批授权）、南京外泌体科技公司（研发液体活检外泌体检测仪器试剂全系列产品，荣获紫金山英才计划高层次创新创业项目）、序贯粒细胞抗癌技术公司（研发全球唯一广谱通用型粒细胞抗癌活性检测疗法，获得中国最大医疗器械服务商奥咨达集团战略签约合作全球注册上市）、深圳朝晖再生基因细胞新药公司。抗疫期间作为联合科研团队研发出首辆核酸采样检测车并拥有两项核心专利知识产权获批（ZL202322774682.9、ZL 202322774685.2），率先捐赠干细胞抗新冠制剂等投入应用于抗疫一线做出应有贡献。疫后参与唯一长新冠健康管理国际合作课题项目，进一步探索医产学研深度融合的新模式新产品，研发先进细胞药械组合创新产品技术的应用及产业化发展。  图片源自武汉医科所 武汉市医科所已完成千万级Pre-A轮融资，用于加速武汉医科所CKA粒细胞抗癌活性诊疗技术核心在研管线战略布局、历史技术积淀产学研转化、若干细胞外泌体药械组合创新产品研发管线以及特色低温医学治疗保存技术市场化应用进程的快速推进。为国家自然科学基金项目、中国博士后科学基金一等课题等国家省部级项目资助主持单位，原《中国临床护理杂志》主编单位。首创提出活性细胞药物属于中医药理论动物药范畴等重大原始理论创新成果。 创始人曾师从干细胞诺贝尔奖得主、粒细胞抗癌理论泰斗 武汉医科所科研团队核心科学家卢博士是同济大学国家公派中美联合培养医学博士，师从美籍华裔科学家、维克森林大学世界抗癌小鼠之父崔征教授，其于2003年首次在世界顶级学术杂志《美国国家科学院院报》上发表一篇关于发现抗癌小鼠的论文，引发世界主流媒体和抗癌领域专家及癌症病人的轰动和长期关注。此外，崔征教授首次提出粒细胞抗癌疗法理论，卢博士师从崔教授读博期间，也创新首次提出CTC/CKA粒细胞抗癌活性检测技术理论。 图片源自武汉医科所 卢博士除任武汉医科所PI首席科学家外，还任中国知识产权出版社《生物医药行业细胞产业法规进展研究》学术专著主编、中国细胞制造创新平台产学研秘书长等；曾主持国家自然科学基金，省部重大科学基金，参与国家重点研发计划。 值得一提的是，卢博士也是目前国内唯一干细胞诺贝尔奖得主实验室博士生研究员，师从全球干细胞领域诺贝尔奖获得者联合课题开展IPS干细胞分化胰腺治疗糖尿病研究。2016年，卢博士以海外专项选聘研究员身份学成回国在武汉医科所科研管理岗任职，同时将国际顶尖细胞领域学术科研经验一并带回，武汉医科所也再度迎来转向引领细胞药械创新研发前沿。 首创序贯粒细胞抗癌活性诊疗一体技术，全球首个广谱通用型天然固有免疫细胞疗法 目前武汉医科所拥有并新研发全球通用型免疫细胞活性粒细胞抗癌序贯疗法和CKA抗癌活性检测技术。需要指出的是，卢博士及崔征教授师生团队两代人接力抗癌展开长达十余年研究的同时，癌症诊疗领域市场也在发生变化。 一方面是CGT的崛起，尽管其在医药领域仍处于早中期阶段，但市场规模已在持续稳定增长。据弗若斯特沙利文预测，全球及中国市场规模将在2025年达到305.4亿美元和178.9亿元，2021-2025年CAGR高达71%和276%，未来市场潜力巨大。其中，预计2024年全球干细胞市场规模将达到177.8亿美元，并将呈爆发性增长趋势。 另一方面是日益增长的癌症患者群体。根据世界卫生组织国际癌症研究机构（IARC）发布的2020年全球最新癌症负担数据，中国已经成为了名副其实的“癌症大国”。2024年中旬，国家癌症中心基于肿瘤登记及随访监测最新数据，与国际肿瘤研究机构（IARC）联合测算，2022年我国癌症新发病例为482.47万例，新发癌症死亡病例257.42万例。发病数的增长和更低的死亡率归因于人口老龄化、较高的筛查率、早期诊断率以及更低的死亡率。 ● 肿瘤早筛痛点CKA粒细胞抗癌活性体外检测技术 现有的肿瘤筛查技术仍存在缺陷：影像学可发现中晚期患者，早期发现较难，且不能区分良恶性；病理学诊断用于鉴别诊断，不能用于筛查，且准确性很大程度取决于采集的样本和观察，人为因素较大；而肿瘤标志物和免疫组化诊断则因技术和应用场景问题发展受阻。 据此，武汉医科所卢博士团队在之前崔征教授研究的基础上，发现人体白细胞中含量最大的粒细胞是体内细胞抗癌活性（Cancer killing activity, CKA）主要载体并提出全球首创液体活检新领域CKA体外检测技术，首次用现代医疗仪器检测具有高抗癌性粒细胞活性来诊断肿瘤癌症，并评估人体抗癌活性。  图片源自武汉医科所 机体内天然固有清除癌细胞的能力又称CKA，可将体内已形成的癌细胞有选择性的杀死，从而高效无毒地保护机体。CKA体外检测技术的优点在于精确度准、特异性强，又因用血量少（仅需数毫升），检测流程快速便捷，未来商业化后定价适中，更易于推广。 CKA抗癌活性体外检测技术和LIFT序贯粒细胞抗癌疗法申请多项知识产权发明专利，如一种通用广谱抗癌活性粒细胞人全血分选方法（中国发明专利）、一种细胞活性检测仪器装置（实用新型专利）等。 截至目前，CKA体外检测技术已在临床前预实验中癌症小鼠模型获得证实，LIFT序贯粒细胞抗癌疗法曾通过FDA批准许可已在多个院校临床医学中心或医院进入临床试验阶段。自从开展基础研究和临床试验以来，没有出现一例不良反应或CKA检测仪器故障事件。 据武汉医科所披露研发进展介绍，CKA体外检测技术在临床诊治过程多个环节均可应用：对于癌症转移者和癌症中晚期者，可进行个体化耐药分析并制定个性化的治疗策略；而筛查早期甚至是超早期癌前病变的高危人群的抗癌活性，能够进行（超）早期肿瘤筛查和术后复发早期监测；对于广大受众健康人群，评估个体粒细胞的抗癌活性，可有助于倡议公众主动预防肿瘤疾病的发生发展，以期为健康中国作出积极贡献和社会价值。 ● 突破性实体瘤LIFT序贯活性粒细胞抗癌疗法 “粒细胞抗癌疗法”是美籍华人科学家崔征博士最早从1999年开始研发，在科研院校和政府的大力支持下进行的研究。参与该项目专业研究的专家团队超过100人，另有世界各地众多科研机构协助；经过十余年全面深入的科学实验，奠定了粒细胞抗癌新疗法的理论体系，是治癌防癌领域历史性突破。 武汉医科所卢博士团队师从于崔征教授并进行传承创新的LIFT序贯活性粒细胞抗癌疗法是基于前期所在国内外科研团队对抗癌小白鼠及抗癌人的研究，发现在健康人体内存在着具有极高水平自然抗癌活性的粒细胞。粒细胞是人体循环中最丰富的白细胞群，在保护宿主免受微生物感染以及炎症过程中起着关键作用。 近年来发现粒细胞在肿瘤的生长和进展中也扮演着重要角色。研究发现不同亚群的粒细胞可能促进或限制肿瘤生长，这提示医学界更加关注中性粒细胞作为癌症治疗目标的潜能。  图片源自武汉医科所 “LIFT序贯粒细胞抗癌疗法”是科研团队十多年研究的基础上，通过抗癌活性功能性检测，采用成分采血方式在健康人群中提取具有高抗癌活性的粒细胞，同时以成分输血的方式将带有这种抗癌活性的粒细胞从健康人供体身上移植到癌症病人的体内，从而达到无痛苦、无毒副作用、无并发症、疗效显著、治疗周期短、可重复治疗、达到广谱性通用抗癌目的。 与传统免疫细胞治疗不同的是，LIFT序贯粒细胞抗疗法是从健康人身上采集粒细胞，并且进行功能性抗癌活性检测后才进行注入。这相当于输血疗法的器官移植。通常粒细胞输入24小时即可以杀死患者体内97%的癌细胞，适用于各种不同病程阶段的肿瘤治疗。 可以说，LIFT序贯粒细抗疗法对传统肿瘤免疫疗法和粒细胞仅抗感染等理论提出冲击和挑战。根据已有临床研究和动物学实验结果，LIFT序贯粒细胞抗疗法首次显示粒细胞用于治疗癌症时在裸鼠体内无任何短期或长期副作用；用粒细胞进行临床实验和治疗，没有有进一步恶化或进一步转移，未来临床目标争取实现与癌共存带癌生存，达到一种非传染性慢性病状态。  “三代之约”，序贯粒细胞抗癌活性检测疗法CKA-LIFT未来 武汉医科所主要技术研发团队目前由干细胞诺贝尔医学奖联合实验室海归博士博士后、高级职称研究员组成，核心科研人员是以上粒细胞抗癌疗法理论的研究继承人和学说完善者。武汉医科所科研团队目前已经全球首创研发攻克了粒细胞抗癌活性检测仪器试剂，突破了粒细胞长期保存液长时间长距离冻存技术瓶颈。 当下国内外细胞治疗包括肿瘤细胞免疫治疗以及干细胞治疗两大类，CAR-T疗法和PD-1/PD-L1免疫疗法分别占据了肿瘤免疫疗法的半边天，而粒细胞抗癌活性诊疗方法的登台，无疑将为肿瘤的细胞治疗带来新的风景，乃至动摇已有格局。 未来的武汉医科所集团将致力于成为引领通用广谱天然固有免疫细胞医学科学新型研发机构创新头部企业，目前CKA-LIFT序贯粒细胞抗癌活性检测疗法项目已经参加“武创源”颠覆技术创新大赛并被推荐至国家科技部2024全国颠覆式技术创新大赛，期待创新加速转化佳绩。 2024生物创新药产业大会现场，图片源自武汉医科所 “序贯粒细胞抗癌活性检测疗法技术的研究，从师从崔征教授到我们武汉医科所科研团队，已经是持续研发第二代了，下一步可能要发展到第三代，希望我们这一代人有望解决学术、临床应用乃至商业化的问题。” 卢博士说，巧合的是，类似武汉医科所从高氏创始人研究所到现在发展为新型研发机构集团，这种传承创新多股力量汇集交织，推动着中国医学界以及全球的医疗健康产业一路向前。 （谨以此文纪念武汉市医学科学研究所五十周年1974-2024） 近 期 推 荐 声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。 动脉网，未来医疗服务平台

CINCINNATI, August 11, 2021 /PRNewswire/ -- Blue Water Vaccines, Inc., a biopharmaceutical company, announced today that it has appointed Dr. Ronald R. Cobb as its Head of Science and Discovery. Dr. Cobb brings with him not only exemplary research and development expertise, but also expertise in leading early-stage drug development from the lab to market. His understanding of drug development from inception to supply chain and beyond will be crucial for Blue Water Vaccine's onward journey. "We welcome Ron as an expert strategist with deep knowledge of developing early-stage drugs into successful assets," said Joseph Hernandez, Chairman and CEO of Blue Water Vaccines. "We look forward to him leading Blue Water Vaccines' pipeline initiatives, which focus on treating and preventing pathogen infections." "I am excited to join the growing team at Blue Water Vaccines and to be involved in the critical process of bringing life-saving vaccines to patients globally," noted Dr. Cobb. "Pathogenic infections like Influenza, Streptococcus pneumoniae, and the norovirus are profound global issues that demand effective solutions. As the head of Blue Water Vaccines' scientific initiatives, I plan to propel these ongoing programs forward and establish their clinical path." Dr. Ron Cobb is a geneticist and a molecular biologist with over 25 years of pharmaceutical R&D and manufacturing experience. In his previous roles, Dr. Cobb was responsible for various leadership positions. He was most recently, the Chief Scientific Officer at Ology Bioservices. At Tanabe Research Laboratories, he initiated discovery programs seeking small molecule inhibitors of inflammatory diseases while supporting all internal drug discovery screening efforts with protein expression services. At Berlex Biosciences (U.S. Division of Schering AG) Dr. Cobb led the protein expression division and supported the research and clinical development phase projects. He was also a member of the Scientific Advisory Committee and Worldwide Antibody Development Committee for Schering-Plough Corporation. Dr. Cobb, as principal investigator, has overseen more than $200M in drug development contracts over his career, and has co-authored over 60 peer-reviewed manuscripts. Dr. Cobb earned his BA in Biology from Wake Forest University and his Ph.D. in Biochemistry from the Medical College of Georgia. Blue Water Vaccines is developing a universal influenza vaccine that could potentially provide lifelong protection from influenza, including pandemic strains like the 1918 pandemic and 2009 swine flu. Scientists from the University of Oxford identified epitopes of limited variability in the head domain of the haemagglutinin protein. These epitopes are targeted naturally by the immune system and vaccination studies have shown that regions of influenza viruses that circulated in 2006 and 1977 were able to protect against infection with an influenza virus that last circulated in 1934. About Blue Water Vaccines Blue Water Vaccines, Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company has licensed a novel virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases. Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent middle ear infections, known as Acute Otitis Media (AOM), in children. The live-attenuated vaccine candidate has been shown to effectively prevent colonization of pneumococcus bacteria in the middle ear of chinchillas regardless of serotype. AOM accounts for approximately 20 million physician visits each year in the United States. Globally, AOM caused by pneumococcus accounts for approximately 300 million cases annually. For more information, visit . Contact Information: Erin Henderson Email: ehenderson@bluewatervaccines.com Olipriya Das (media) Email: olipriya.das@russopartnersllc.com